BrainChild Bio · 2 hours ago
Scientist, Analytical Development
BrainChild Bio is seeking to hire an experienced Scientist in Analytical Development to add to our growing team supporting clinical development of CAR T therapies to treat pediatric brain malignancies. The Scientist will be responsible for the design, development, qualification and transfer of flow cytometry methods to support cellular drug product and vector drug substance GMP-release and characterization.
BiotechnologyTherapeutics
Responsibilities
Work collaboratively with internal BrainChild Bio Research, Process Development and Analytical Development teams and with external partners at contract manufacturing organizations
Design, develop and qualify flow cytometry and spectral cytometry methods for release and characterization of pre-clinical through late-stage CAR T programs
Independently lead analytical method transfers and support existing method life cycle management at contract manufacturing organizations
Author ELNs, SOPs, protocols and reports
Review and approve contract manufacturing organization methods, protocols and reports
Manage direct reports
Qualification
Required
Degree in biology, bioengineering, immunology, virology, microbiology or related discipline
Scientist qualifications include PhD with 0-2 years, MA/MS with 4-6 years, or BA/BS with 6-8 years of experience
Experience managing and collaborating with contract manufacturing organizations
Hands-on experience designing, developing, qualifying and transferring flow cytometry and spectral assays for QC release and/or characterization
A team player with a track record of successfully operating within cross-functional teams
Proficiency with life science data analysis tools (FlowJo, Prism, JMP, Excel, etc.)
Preferred
Experience with a broad range of cytometry platforms (BD, Beckman, Cytek, Sony, etc.) is highly desired
Previous experience with analytical method qualification, transfer and life cycle management desired
Company
BrainChild Bio
BrainChild Bio develops CAR-T cell therapies for pediatric brain tumors, focusing on DIPG.
Funding
Current Stage
Early StageTotal Funding
$0.3MKey Investors
ScaleReady
2025-01-21Grant· $0.3M
Recent News
Company data provided by crunchbase